Benmelstobart
- Generic Name
- Benmelstobart
- Brand Names
- 安得卫
- Drug Type
- -
- Chemical Formula
- -
- CAS Number
- -
- Unique Ingredient Identifier
- -
- Indication
联合盐酸安罗替尼胶囊、卡铂和依托泊苷用于广泛期小细胞肺癌（ES-SCLC）的一线治疗。
- Associated Conditions
- -
- Associated Therapies
- -
Phase II Study of Golidocitinib and Benmelstobart in Patients with R/R ENKTL (JACKPOT50)
Phase 2
Not yet recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-12-13
- Last Posted Date
- 2024-12-13
- Lead Sponsor
- Sun Yat-sen University
- Target Recruit Count
- 47
- Registration Number
- NCT06733051
- Locations
- 🇨🇳
Beijing Tongren Hospital, Beijing, Beijing, China
🇨🇳Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
Neoadjuvant Therapy of Targeted Immunotherapy Combined With Chemotherapy for Locally Advanced HNSCC
Phase 2
Not yet recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-11-21
- Last Posted Date
- 2024-11-21
- Target Recruit Count
- 45
- Registration Number
- NCT06699498
- Locations
- 🇨🇳
The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, China
The Efficacy and Safety of Benmelstobart for GC/EGC
Not Applicable
Not yet recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-09-19
- Last Posted Date
- 2024-09-19
- Lead Sponsor
- Xijing Hospital
- Target Recruit Count
- 48
- Registration Number
- NCT06603974
Adjuvant Benmelstobart for Stage IB, Grade 3 Invasive Lung Adenocarcinoma
- First Posted Date
- 2024-07-30
- Last Posted Date
- 2024-07-31
- Lead Sponsor
- Shanghai Pulmonary Hospital, Shanghai, China
- Target Recruit Count
- 62
- Registration Number
- NCT06528847
- Locations
- 🇨🇳
Shanghai Pulmonary Hospital, Shanghai, Shanghai, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath